Document is current
Any future updates will be listed below
-
Authors
Rosenberger, Florian A. https://orcid.org/0000-0003-4604-6170
Mädler, Sophia C. https://orcid.org/0000-0001-7817-4180
Thorhauge, Katrine Holtz https://orcid.org/0000-0003-0411-0373
Steigerwald, Sophia
Fromme, Malin https://orcid.org/0000-0003-0382-5705
Lebedev, Mikhail https://orcid.org/0009-0008-3646-7899
Weiss, Caroline A. M.
Oeller, Marc https://orcid.org/0000-0003-0597-5950
Wahle, Maria https://orcid.org/0000-0003-2079-4402
Metousis, Andreas https://orcid.org/0000-0002-1043-6591
Zwiebel, Maximilian https://orcid.org/0000-0002-7005-5619
Schmacke, Niklas A. https://orcid.org/0000-0002-3998-1139
Detlefsen, Sönke https://orcid.org/0000-0002-9466-2333
Boor, Peter https://orcid.org/0000-0001-9921-4284
Fabián, Ondřej
Fraňková, Soňa
Krag, Aleksander https://orcid.org/0000-0002-9598-4932
Strnad, Pavel
Mann, Matthias https://orcid.org/0000-0003-1292-4799
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 11 March 2025
First Online: 16 April 2025
Competing interests
: M.M. is an indirect investor in Evosep. A patent for treatment of conditions related to α1-antitrypsin deficiency with PPARα agonists has been filed with the European Patent Office (application number EP24205578.8). The other authors declare no competing interests.
